



Online Program Schedule
Collaborating to Move Research Forward

Friday, August 6, 2021

- 11:00 – 12:30 **Meet & Greet** – Login early to our Think Tank platform to meet your colleagues online to catch up, talk about research, or join the consensus group discussion of clinical trial design and endpoints in bladder cancer.
- Consensus group discussion:** Co-Chairs Ashish Kamat, MD and Matthew Galsky, MD invite you to join the discussion! Trial design is of the utmost importance to optimize the efficiency and efficacy of a trial. The end goals are better treatment options and outcomes for patients via evidence-based practice. Setting trial design standards additionally benefits both patients and researchers by creating more comparable and robust data sets. SITC, in collaboration with the International Bladder Cancer Group (IBCG), established a manuscript development group (MDG) to develop a white paper to provide guidance on optimal design of clinical trials specifically for patients with bladder cancer. This white paper will focus on all stages of bladder cancer and expand upon the IBCG guidance for NMIBC (2016 JCO publication) which is referenced by FDA in its guidance document. This jointly developed white paper is intended to be completed in 2021 and submitted for publication to the *Journal for ImmunoTherapy of Cancer (JITC)*. All are welcome.
- Round Table Meet Ups** – Log in early to access the meeting platform, then join a group to connect or meet others:
 RN/Advanced Practitioners – Mary Dunn, MSN, RN, OCN, NP-C, Moderator
 BCAN Patient Advocates – Karen Saches, RN, MSN, Moderator
- 12:30 - 12:45 **Welcome Remarks** | Think Tank 2021 Co-Chairs Matt Galsky, MD, Sima Porten, MD and BCAN Co-Founder Diane Zipursky Quale
- 12:45 – 1:15 **Bladder Cancer Research Innovation Awardee**, Michael M. Shen, PhD, presenting his 2018 BCAN funded project “Modeling bladder cancer metastasis using human patient-derived tumor organoids.” Moderator: Sima Porten, MD

1:15 – 2:45

Tuning the Immune Microenvironment for Immunotherapy Response.

Co-Chairs Ben Vincent, MD, and Thomas Powles, MBBS, MRCP, MD.

The tumor microenvironment (TME) includes surrounding blood vessels, immune cells, fibroblasts, signaling molecules and the extracellular matrix. The TME and tumor are closely related and interact constantly to both support and impair tumor growth. This session will explore the following questions: How does the TME influence response to immunotherapy like BCG or immune checkpoint blockade? What cells and molecular pathways are critical for immunotherapy activity? How can we use current and developing therapies that modulate the TME to improve likelihood and duration of immunotherapy response?

Invited Panel:

Max Kates, MD

William Y. Kim, MD

Joshua J. Meeks, MD, PhD

Nina Bhardwaj, MD, PhD

2:45 – 3:00

Break

3:00 – 4:30

Breakout sessions (select your first and second choice):

Artificial Intelligence – Emerging and Evolving Roles in Bladder

Cancer. Co-Chairs Hikmat Al-Ahmadie, MD, and Olivier Elemento, PhD.

An increasing number of studies suggest that artificial intelligence (AI) will revolutionize medicine. This session will focus on recent advances in AI and its evolving roles in healthcare focusing on applications to bladder cancer. Panelists will also examine how AI will enhance microscopic/pathologic tumor evaluation, the role of AI in radiology and radiomics, and how AI can be used to predict response to therapy.

Invited Speaker:

Joseph Shirk, MD

Pegah Khosravi, PhD

Bishoy Faltas, MD

Biologic Sex Differences in Bladder Cancer. Co-Chairs Debasish Sundi, MD and Sean Li, MD.

Sex disparities in bladder cancer are notable (male to female incidence ratio is 4:1, for example), but the biologic reasons for this are unknown. In this session, we will discuss emerging evidence that suggests that sex influences the ability of bladder cancers to establish and/or proliferate. We will investigate sex-specific differences in anti-tumor immunity and also explore the role of key transcription factors and if/how sex-specific hormonal differences factor in. We will also analyze how sex influences the immune response against bladder cancers treated with immunotherapies.

Invited Speakers:

Sarah C. Markt, ScD, MPH
Hyunwoo (Tony) Kwon, PhD
Molly Ingersoll, PhD

Integrating Complementary and Alternative Medicine Cancer Care: Focus on Bladder Cancer. Co-Chairs Sanjay Reddy, MD, FACP, and Viraj Master, MD, PhD, FACS.

Complementary and alternative medicine (CAM) are not thought of as standard medical care and even less is known about many CAM therapies and how they may benefit bladder cancer patients. Panelists will discuss diet, exercise, supplements and herbs-including safety concerns, mind-body techniques, non-pharmacologic tools for symptom management, and the role of medical cannabis.

Long Term Management of Urinary Diversions – Beyond Selection to Management of Diversions. Co-Chairs Anne Schuckman, MD, Kamal Pohar, MD and Sylvia Rodriguez, MS

Urinary reconstruction and diversion are surgical methods to create a new way to pass urine after the bladder has been removed. This session will address stomal issues related to continent cutaneous diversions and ileal conduits, including long term metabolic and nutritional issues for patients with urinary diversions, issues related to continence in neobladders with aging, and changes in renal function over time. Panelists will also discuss surgical and non-surgical "mechanical" issues such as ureteral strictures and prolapse.

Invited Speakers:

Miriam Quinn, BSN, CWON
Debra McCamish, RN, CWON

Starting Early: Perioperative Optimization Interventions to Enhance Outcomes for Radical Cystectomy. Co-Chairs Sarah Psutka, MD, MSc, and Sia Daneshmand, MD.

Panelists discuss strategies that can be offered to patients to optimize performance and health prior to a radical cystectomy. They will also focus on nutritional optimization, exercise interventions, and identification of other patient-specific vulnerabilities, as well as novel risk stratification measures including frailty, body composition, and multidimensional risk assessments.

Invited Speakers:

Jill M. Hamilton-Reeves, PhD, RD, CSO

Jeffrey S. Montgomery, MD

Sara Parke, MD

Target Practice in Urothelial Cancer - Managing 'Tox' Outside the Box... Co-Chairs Arlene O. Siefker-Radtke, MD, and Chris Hoimes, DO.

This session will focus on prevention, recognition, and management of toxicity that can arise during treatment to help guide patients through the tradeoffs that may occur. The discussion will focus on toxicity related to FGFR inhibitors, antibody-drug conjugates, and immune checkpoint inhibition.

BCG Shortage Update – Alternatives in the Market. Co-Chairs Chana Weinstock, MD, and Peter Bross, MD.

Session panelists will discuss regulatory perspectives related to the implications of the ongoing BCG shortage on patient care, as well as current FDA thinking on trial design issues that might arise as a result. Panelists will also discuss helping patients navigate the BCG shortage.

Invited Speakers:

Gary D. Steinberg, MD

Robert Svatek, MD

Lowering Bladder Cancer Costs: A Targeted Approach. Co-Chairs
Matthew Mossanen, MD, MPH, and Benjamin T. Ristau, MD, MHA

In this session, participants will discuss several areas of bladder cancer care for superficial and invasive disease to determine possible areas where costs can be lowered while preserving quality. Several possible project ideas will be shared and discussed in detail while the group brainstorms on the most actionable topics.

Invited Speaker:

Deborah Kaye, MD, MS

Funding for Bladder Cancer the Early-Stage Investigator: Nuts and Bolts Co-Chairs Philip Abbosh, MD, PhD and Byron Lee, MD, PhD

This breakout session will focus on the different federal and private funding opportunities available to bladder cancer researchers with emphasis on opportunities for early investigators. We will host a panel of officers from each funding source with intent to query best practices for the preapplication, application, and post application stage, the grant review process, the different tiers of review at each funding source. We will try to identify project themes that might fit better under one funding source or funding opportunity vs. another.

Invited Speakers:

Elisa Woodhouse, PhD

Molly Ingersoll, PhD

4:30 – 4:45

Break

4:45 – 6:00

BCAN's Got Talent – first ever virtual talent show, with the bladder cancer community's very own Master-of-Ceremonies extraordinaire, medical oncologist Sumanta (Monty) Pal, MD

The COVID pandemic has forced many of us to learn or improve on a talent, alone or with our families. The BCAN 2021 Think Tank has a special way to connect with our research community and showcase those hidden talents! [Register to share](#) your talents!

6:00 – 7:00

Networking Happy Hour – meet your colleagues one-on-one or in small groups for a video chat and collaborative discussion from the safety and comfort of your own home. BYOB

Saturday, August 7

- 9:30 – 10:15 **Networking Coffee Hour** – enjoy a cup of coffee and a video chat with a colleague or join the continued consensus group discussion of clinical trial design and endpoints in bladder cancer.
- 10:15 – 10:20 Welcome and preview of Saturday Agenda
- 10:20 – 11:00 **BCAN 2019 New Discoveries Research Young Investigator Awardees:**
- Dr. Neelam Mukherjee presenting her research, “Recombinant CCL2 as a Novel Treatment Strategy for Bladder Cancer.”
 - Dr. Sarah Psutka, presenting her research, “Quantifying Risk and Resilience Among Patients with Bladder Cancer: A Novel Personalized, Comprehensive Risk Stratification Program.”
 - Dr. Sumeet Bhanvadia presenting her **Patient Centered Clinical Research Young Investigator** research, “Understanding the Burden and Impact of Financial Toxicity in Bladder Cancer—A Mixed Methods Study of Two Diverse Patient Populations.”
- 11:00 – 12:30 Breakout sessions (please select your first and second choice):
- Artificial Intelligence – Emerging and Evolving Roles in Bladder Cancer.** Co-Chairs Hikmat Al-Ahmadie, MD, and Olivier Elemento, PhD. (Repeated)
- Biologic Sex Differences in Bladder Cancer.** Co-Chairs Debasish Sundi, MD, and Sean Li, MD. (Repeated)
- Integrating Complementary and Alternative Medicine Cancer Care: Focus on Bladder Cancer.** Co-Chairs Sanjay Reddy, MD, FACP, and Viraj Master, MD, PhD, FACS. (Repeated)
- Long Term Management of Urinary Diversions – Beyond Selection to Management of Diversions.** Co-Chairs Anne Schuckman, MD, and Kamal Pohar, MD. (Repeated)
- Starting Early: Perioperative Optimization Interventions to Enhance Outcomes for Radical Cystectomy.** Co-Chairs Sarah Psutka, MD, MSc, and Sia Daneshmand, MD (Repeated)
- Target Practice in Urothelial Cancer - Managing ‘Tox’ Outside the Box...** Co-Chairs Arlene O. Siefker-Radtke, MD, and Chris Hoimes, DO. (Repeated)

Hematuria: the gateway to bladder cancer diagnosis. Controversies regarding current management of patients with hematuria, anticipated impact of new guidelines, and the future of bladder cancer detection. Co-Chairs Yair Lotan, MD, Dan Barocas, MD, MPH, FACS, and Robert Lipman, BCAN Research Advocate

In May 2020, the American Urological Association released the new Hematuria Guidelines with a risk-based approach. This breakout will discuss issues with noncompliance with prior guidelines, ways to improve triaging and evaluation of hematuria, ways to disseminate guideline recommendations to primary care physicians, and potential incorporation of urine markers in detection algorithms.

Removing Roadblocks to Collaboration – Connecting Community and Academic Practice. Co-Chairs Helen Moon, MD, and Nicholas J. Vogelzang MD, FASCO, FACP.

Lively debate hosted by Dr. Nicholas Vogelzang, current chair of SWOG GU and Dr. Helen Moon, current genitourinary lead for Kaiser Permanente Southern California as the panel discuss the known competition and roadblocks to collaboration Removing Roadblocks to Collaboration – Connecting Community and Academic Practice between the academic and community practices. This breakout session will note current changes that are a reality for many bladder cancer patients. Help map out solutions, build bridges and detours around common roadblocks to continue the path to better patient care and outcomes.

Invited Speaker:

Eugene Y. Rhee, MD
Stephen G. Williams, MD
Marc Dall 'Era, MD

BCG Unresponsive NMIBC. Co-Chairs Eugene Pietzak, MD, Sumeet Bhanvadia, MD, Kelly Stratton MD, and Janet Kukreja, MD

Despite the recent and anticipated FDA approval of novel agents for BCG unresponsive NMIBC, the lack of durable benefit for these treatments necessitates radical cystectomy for many patients. In this session, we will summarize the evidence supporting these agents and engage in a multi-disciplinary discussion on trial design that will include rational combinations of novel agents, practical approaches to future comparative studies, and biomarker development to provide insight on which patients will benefit from which treatment(s). We will also discuss how best to develop data-driven clinical trial inclusion/exclusion criteria for the many

patients with recurrent NMIBC who are not eligible for BCG unresponsive trials but need novel therapies to prevent the development of BCG unresponsive disease.

12:30 – 1:00 Break

1:00 – 2:00 Meet the 2020 John Quale Travel Fellows

Due to the pandemic, BCAN postponed our introduction of the dynamic young clinicians and researchers who received the 2020 John Quale Travel Fellowships. Join us for an interactive hour to learn about their research and welcome them to the bladder cancer community! Moderated by Petros Grivas, MD, PhD.

- Nathan Brooks, MD
- John Christin, MD, PhD
- Carissa Chu, MD
- Ali Khaki, MD
- Richard Matulewicz, MD
- Jeffrey Wong, MD, PhD

2:00 – 3:30 **Making Sense of Germline Variants in Bladder Cancer.** Co-Chairs Kent W. Mouw, MD, PhD, and Bishoy M. Faltas, MD
Inherited (germline) mutations can impact the risk of cancer development. Emerging evidence suggests that hereditary factors may also play a role in the development and the clinical course of bladder cancer. This session will highlight recent efforts to define the role of inherited mutations in bladder cancer, including risk assessment, screening, variant calling, and implications for bladder cancer treatment and outcomes.

Invited Panel:

María Carlo, MD
Saud H. Al Dubayan, MD
Ludmilla Prokunina-Olsson, PhD

3:30 – 3:45 **Wrap Up** – Closing Comments – and BCAN's Got Talent recognition.

3:45 – 5:00 The Think Tank meeting platform will remain open for individual or group networking or follow-on conversations.